Trial · NCT00312377
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) in the Overall Population | Vandetanib 100 mg Plus Docetaxel | 17.3 | 95% Confidence Interval 15 to 18 | Weeks | |
| Progression-Free Survival (PFS) in the Overall Population | Placebo Plus Docetaxel | 14 | 95% Confidence Interval 12.7 to 16.9 | Weeks | |
| Progression-Free Survival (PFS) in the Female Population | Vandetanib 100 mg Plus Docetaxel | 20.1 | 95% Confidence Interval 17.9 to 23.9 | Weeks | |
| Progression-Free Survival (PFS) in the Female Population | Placebo Plus Docetaxel | 18.3 | 95% Confidence Interval 15 to 22.1 | Weeks | |
| Overall Survival (OS) in the Overall Population | Vandetanib 100 mg Plus Docetaxel | 10.6 | 95% Confidence Interval 9.6 to 11.5 | Months | |
| Overall Survival (OS) in the Overall Population | Placebo Plus Docetaxel | 10 | 95% Confidence Interval 9.2 to 10.8 | Months | |
| Overall Survival (OS) in the Female Population | Vandetanib 100 mg Plus Docetaxel | 12.7 | 95% Confidence Interval 10.5 to 17.1 | Months | |
| Overall Survival (OS) in the Female Population | Placebo Plus Docetaxel | 14.2 | 95% Confidence Interval 10.8 to 16.2 | Months | |
| Objective Response Rate (ORR) | Vandetanib 100 mg Plus Docetaxel | 120 | Participants | ||
| Objective Response Rate (ORR) | Placebo Plus Docetaxel | 71 | Participants | ||
| Disease Control Rate (DCR) | Vandetanib 100 mg Plus Docetaxel | 413 | Participants | ||
| Disease Control Rate (DCR) | Placebo Plus Docetaxel | 380 | Participants | ||
| Duration of Response (DoR) | Vandetanib 100 mg Plus Docetaxel | 29.9 | Full Range 7.14 to 72.29 | Weeks | |
| Duration of Response (DoR) | Placebo Plus Docetaxel | 19.7 | Full Range 9.71 to 41.86 | Weeks | |
| Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS). | Vandetanib 100 mg Plus Docetaxel | 15 | Inter-Quartile Range 6.1 to 82.3 | Weeks | |
| Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS). | Placebo Plus Docetaxel | 11.9 | Inter-Quartile Range 6.0 to 28.1 | Weeks | |
| Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI) | Vandetanib 100 mg Plus Docetaxel | 12.3 | Inter-Quartile Range 5.9 to 36.7 | Weeks | |
| Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI) | Placebo Plus Docetaxel | 11.9 | Inter-Quartile Range 6 to 28.4 | Weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00312377/results